Beta-2 Adrenergic Receptor

From Proteopedia

(Difference between revisions)
Jump to: navigation, search
Line 1: Line 1:
<StructureSection load='1dq8' size='490' side='right' caption='Solved Structures of a Beta 2-Adrenergic Receptor' scene=' ' >
<StructureSection load='1dq8' size='490' side='right' caption='Solved Structures of a Beta 2-Adrenergic Receptor' scene=' ' >
-
[[Image: |120px|left]]&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; [[Beta-2 Adrenergic Receptor]]'''s''' (B2ARs) are a type of G Protein-Coupled Receptor (GPCR). GPCRs are the largest family of integral membrane proteins in the human body with over 1000 unique Isoforms. B2AR is activated by hormone ligands like adrenaline (epinephrine) and noradrenaline and plays a critical role in cardiovascular and pulmonary physiology. Binding of adrenaline by B2AR causes a sympathetic nervous system response like the well-known “flight or flight response”, resulting in an increased heart rate, pupil dilation, rapid energy mobilization and diversion of blood to skeletal muscle. More precisely, upon binding a ligand, B2AR activates [[Adenylyl cyclase]] through interaction with B2ARs C-terminus. Adenylyl cyclase subsequently converts ATP into cAMP, which functions as a downstream signaling molecule activating effectors like cAMP-dependent protein kinases, resulting in various bodily responses. <ref name="Witter"/>
+
[[Image: |120px|left]]&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; [[Beta-2 Adrenergic Receptor]]'''s''' (B2ARs) are a type of G Protein-Coupled Receptor (GPCR). GPCRs are the largest family of integral membrane proteins in the human body with over 1000 unique Isoforms. B2AR is activated by hormone ligands like adrenaline (epinephrine) and noradrenaline and plays a critical role in cardiovascular and pulmonary physiology. Binding of adrenaline by B2AR causes a sympathetic nervous system response like the well-known “flight or flight response”, resulting in an increased heart rate, pupil dilation, rapid energy mobilization and diversion of blood to skeletal muscle. More precisely, upon binding a ligand, B2AR activates [[Adenylyl cyclase]] through interaction with B2ARs C-terminus. Adenylyl cyclase subsequently converts ATP into cAMP, which functions as a downstream signaling molecule activating effectors like cAMP-dependent protein kinases, resulting in various bodily responses.<ref name="Witter"/>
-
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;During embryo development, Beta adrenergic receptors are involved in fetal growth, tissue differentiation and axonal outgrowth. During fetus development, B2AR transcription is progressively downregulated and undergoes desensitization. These steps are essential homeostatic mechanisms to prevent cells from being overly stimulated and maintaining the correct sympathetic to parasympathetic tone. This sympathetic-parasympathetic tone determines the point at which the sympathetic nervous system (flight or fight) overrides the parasympathetic nervous system (responsible for normal cardiovascular homeostasis). The B2AR downregulation and desensitization steps are first established during prenatal development during the first and second trimester.<ref name="Witter">PMID: 19961985</ref> Interestingly, overstimulation of B2ARs during critical periods of prenatal development can cause a permanent increase in the sympathetic to parasympathetic tone. Overstimulation of this type is caused by stress in the mother for reasons ranging from infections to hardships like natural disasters. Since children with autism typically have an elevated sympathetic tone and elevated B2AR stimulation during development causes an elevated sympathetic tone, this partly explains why children of mothers who survive natural disasters during pregnancy have a higher incidence of [[Autism Spectrum Disorders]] (ASDs).
+
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;During embryo development, Beta adrenergic receptors are involved in fetal growth, tissue differentiation and axonal outgrowth. During fetus development, B2AR transcription is progressively downregulated and undergoes desensitization. These steps are essential homeostatic mechanisms to prevent cells from being overly stimulated and maintaining the correct sympathetic to parasympathetic tone. This sympathetic-parasympathetic tone determines the point at which the sympathetic nervous system (flight or fight) overrides the parasympathetic nervous system (responsible for normal cardiovascular homeostasis). The B2AR downregulation and desensitization steps are first established during prenatal development during the first and second trimester.<ref name="Witter">PMID: 19961985</ref> Interestingly, overstimulation of B2ARs during critical periods of prenatal development can cause a permanent increase in the sympathetic to parasympathetic tone. Overstimulation of this type is caused by stress in the mother for reasons ranging from infections to hardships like natural disasters. Since children with autism typically have an elevated sympathetic tone and elevated B2AR stimulation during development causes an elevated sympathetic tone, this partly explains why children of mothers who survive natural disasters during pregnancy have a higher incidence of [[Autism Spectrum Disorders]] (ASDs).<ref name="Witter"/>
 +
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As an aside, stress during prenatal development has also been proven to impact locus coeruelus (LC) development. Nearly all adrenaline in the brain is produced and transported by neurons in the Locus Coeruleous, a small area of the brain. The locus coeruleus-Noradrenergic System (LC-NA) plays a crucial role in virtually all aspects of behavioral adaptations and performance of cognitive regions of the brain commonly affected in ASDs.<ref name="Purpura">PMID: 19059284</ref> Critical enzymes for proper LC can be downregulated by aberrant epigenetic modifications caused by prenatal stress. One well known example of this is hypomethylation of the Crh gene. When methylated, the Crh promotor is bound by the transcriptional repressor, [[MeCP2]]. Aberrant epigenetic modifications caused by prenatal stress can cause Crh promoters to be under methylated, preventing MeCp2 binding and subsequently causing overexpression of the Crh gene. Overexpression of the Crh gene is a trademark of Rett Syndrome, a well known [[Neurodevelopmental Disorders|neurodevelopmental disorder]] Interestingly, when some autism patients have a fever, the LC-NA system dysfunction abates resulting in reduced autistic behaviors. This implies that the underlying neural networks mediating the LC-NA system are still functional, and offers hope for partial reversal of ASDs through [[Pharmaceutical Drugs|pharmaceutical intervention]]. <ref name="Purpura"/>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As an aside, stress during prenatal development has also been proven to impact locus coeruelus (LC) development. Nearly all adrenaline in the brain is produced and transported by neurons in the Locus Coeruleous, a small area of the brain. The locus coeruleus-Noradrenergic System (LC-NA) plays a crucial role in virtually all aspects of behavioral adaptations and performance of cognitive regions of the brain commonly affected in ASDs.<ref name="Purpura">PMID: 19059284</ref> Critical enzymes for proper LC can be downregulated by aberrant epigenetic modifications caused by prenatal stress. One well known example of this is hypomethylation of the Crh gene. When methylated, the Crh promotor is bound by the transcriptional repressor, [[MeCP2]]. Aberrant epigenetic modifications caused by prenatal stress can cause Crh promoters to be under methylated, preventing MeCp2 binding and subsequently causing overexpression of the Crh gene. Overexpression of the Crh gene is a trademark of Rett Syndrome, a well known [[Neurodevelopmental Disorders|neurodevelopmental disorder]] Interestingly, when some autism patients have a fever, the LC-NA system dysfunction abates resulting in reduced autistic behaviors. This implies that the underlying neural networks mediating the LC-NA system are still functional, and offers hope for partial reversal of ASDs through [[Pharmaceutical Drugs|pharmaceutical intervention]]. <ref name="Purpura"/>

Revision as of 04:33, 3 April 2011

Solved Structures of a Beta 2-Adrenergic Receptor

Drag the structure with the mouse to rotate

References

  1. 1.0 1.1 1.2 Witter FR, Zimmerman AW, Reichmann JP, Connors SL. In utero beta 2 adrenergic agonist exposure and adverse neurophysiologic and behavioral outcomes. Am J Obstet Gynecol. 2009 Dec;201(6):553-9. PMID:19961985 doi:10.1016/j.ajog.2009.07.010
  2. 2.0 2.1 Mehler MF, Purpura DP. Autism, fever, epigenetics and the locus coeruleus. Brain Res Rev. 2009 Mar;59(2):388-92. Epub 2008 Nov 24. PMID:19059284 doi:10.1016/j.brainresrev.2008.11.001
  3. Rasmussen SG, Choi HJ, Rosenbaum DM, Kobilka TS, Thian FS, Edwards PC, Burghammer M, Ratnala VR, Sanishvili R, Fischetti RF, Schertler GF, Weis WI, Kobilka BK. Crystal structure of the human beta2 adrenergic G-protein-coupled receptor. Nature. 2007 Nov 15;450(7168):383-7. Epub 2007 Oct 21. PMID:17952055 doi:10.1038/nature06325
  4. Cherezov V, Rosenbaum DM, Hanson MA, Rasmussen SG, Thian FS, Kobilka TS, Choi HJ, Kuhn P, Weis WI, Kobilka BK, Stevens RC. High-resolution crystal structure of an engineered human beta2-adrenergic G protein-coupled receptor. Science. 2007 Nov 23;318(5854):1258-65. Epub 2007 Oct 25. PMID:17962520
  5. Hanson MA, Cherezov V, Griffith MT, Roth CB, Jaakola VP, Chien EY, Velasquez J, Kuhn P, Stevens RC. A specific cholesterol binding site is established by the 2.8 A structure of the human beta2-adrenergic receptor. Structure. 2008 Jun;16(6):897-905. PMID:18547522 doi:10.1016/j.str.2008.05.001
  6. Scheerer P, Park JH, Hildebrand PW, Kim YJ, Krauss N, Choe HW, Hofmann KP, Ernst OP. Crystal structure of opsin in its G-protein-interacting conformation. Nature. 2008 Sep 25;455(7212):497-502. PMID:18818650 doi:10.1038/nature07330
  7. Warne T, Moukhametzianov R, Baker JG, Nehme R, Edwards PC, Leslie AG, Schertler GF, Tate CG. The structural basis for agonist and partial agonist action on a beta(1)-adrenergic receptor. Nature. 2011 Jan 13;469(7329):241-4. PMID:21228877 doi:10.1038/nature09746
  8. Cruickshank JM. Beta blockers in hypertension. Lancet. 2010 Aug 7;376(9739):415; author reply 415-6. PMID:20692524 doi:10.1016/S0140-6736(10)61217-2
Personal tools